Entheon Biomedical Corp. (CSE:ENBI)
Canada
· Delayed Price · Currency is CAD 0.100
0.00 (0.00%)
Dec 18, 2025, 3:06 PM EST
Entheon Biomedical Income Statement
Financials in millions CAD. Fiscal year is December - November.
Millions CAD. Fiscal year is Dec - Nov.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Feb '26 Feb 28, 2026 | Nov '25 Nov 30, 2025 | Nov '24 Nov 30, 2024 | Nov '23 Nov 30, 2023 | Nov '22 Nov 30, 2022 | Nov '21 Nov 30, 2021 | 2020 - 2019 |
| Revenue | - | - | - | 0.25 | 0.19 | - | Upgrade
|
| Revenue Growth (YoY) | - | - | - | 31.97% | - | - | Upgrade
|
| Gross Profit | - | - | - | 0.25 | 0.19 | - | Upgrade
|
| Selling, General & Admin | 0.28 | 0.33 | 0.33 | 0.56 | 2.5 | 4.45 | Upgrade
|
| Research & Development | - | - | - | - | 1.2 | 1.21 | Upgrade
|
| Operating Expenses | 0.29 | 0.33 | 0.33 | 0.56 | 3.79 | 8.21 | Upgrade
|
| Operating Income | -0.29 | -0.33 | -0.33 | -0.31 | -3.6 | -8.21 | Upgrade
|
| Interest & Investment Income | 0.01 | 0.01 | 0.02 | 0.01 | 0 | 0.01 | Upgrade
|
| Currency Exchange Gain (Loss) | -0 | -0 | -0 | -0 | 0.02 | 0 | Upgrade
|
| Other Non Operating Income (Expenses) | 0 | - | - | 0 | 0.25 | -0 | Upgrade
|
| EBT Excluding Unusual Items | -0.28 | -0.32 | -0.32 | -0.3 | -3.33 | -8.2 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | 0 | -0.07 | 0.21 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | 1.34 | - | Upgrade
|
| Pretax Income | -0.28 | -0.32 | -0.32 | -0.3 | -2.06 | -8 | Upgrade
|
| Earnings From Continuing Operations | -0.28 | -0.32 | -0.32 | -0.3 | -2.06 | -8 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | - | -6.46 | -0.89 | Upgrade
|
| Net Income | -0.28 | -0.32 | -0.32 | -0.3 | -8.52 | -8.89 | Upgrade
|
| Net Income to Common | -0.28 | -0.32 | -0.32 | -0.3 | -8.52 | -8.89 | Upgrade
|
| Shares Outstanding (Basic) | 16 | 13 | 8 | 6 | 6 | 5 | Upgrade
|
| Shares Outstanding (Diluted) | 16 | 13 | 8 | 6 | 6 | 5 | Upgrade
|
| Shares Change (YoY) | 67.81% | 73.25% | 30.96% | - | 8.85% | 97.83% | Upgrade
|
| EPS (Basic) | -0.02 | -0.02 | -0.04 | -0.05 | -1.44 | -1.64 | Upgrade
|
| EPS (Diluted) | -0.02 | -0.02 | -0.04 | -0.05 | -1.44 | -1.64 | Upgrade
|
| Free Cash Flow | -0.26 | -0.31 | -0.36 | -0.36 | -1.95 | -5.33 | Upgrade
|
| Free Cash Flow Per Share | -0.02 | -0.02 | -0.05 | -0.06 | -0.33 | -0.98 | Upgrade
|
| Gross Margin | - | - | - | 100.00% | 100.00% | - | Upgrade
|
| Operating Margin | - | - | - | -124.96% | -1898.18% | - | Upgrade
|
| Profit Margin | - | - | - | -119.85% | -4492.23% | - | Upgrade
|
| Free Cash Flow Margin | - | - | - | -143.79% | -1030.49% | - | Upgrade
|
| EBITDA | - | - | - | - | -3.6 | -8.18 | Upgrade
|
| D&A For EBITDA | - | - | - | - | 0 | 0.04 | Upgrade
|
| EBIT | -0.29 | -0.33 | -0.33 | -0.31 | -3.6 | -8.21 | Upgrade
|
| EBIT Margin | - | - | - | -124.96% | - | - | Upgrade
|
| Revenue as Reported | - | - | - | 0.25 | 0.19 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.